BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1998

View Archived Issues

New azapeptide HIV protease inhibitor profiled at ICAAC

Read More

Guilford achieves development milestone in Amgen collaboration

Read More

A novel use described for the proton pump inhibitor pantoprazole

Read More

Celgene initiates development of Thalomid for hematological cancers

Read More

Neurotrophic/neuroprotective compounds claimed by Sanofi

Read More

New arthritis Rx now available in Japan

Read More

Sanofi describes new series acting on vasopressin and/or oxytocin receptors

Read More

Peptide analgesics described by Asahi Glass

Read More

Antisecretory benzodiazepines for GI disorders designed at Zeria

Read More

PowderJect system effectively delivers local anesthetic without a needle

Read More

Dual LTD4 antagonists/histamine release inhibitors in development at Daiichi

Read More

Chrysalis begins clinical evaluation of wound-healing agent

Read More

Nyotran effective against treatment-resistant fungal infections in phase II study

Read More

Pyrrole antiviral agents prepared and evaluated at Rhone-Poulenc Rorer

Read More

Yamanouchi and Merck KGaA work together to develop Na+/H+ exchange inhibitors

Read More

Yoshitomi optimizes quinolones for anti-H. pylori activity: selects Y-34867 as development candidate

Read More

SYN-2869: new triazole antifungal agent selected for further development

Read More

New study shows that LYMErix can be given according to a flexible dosing schedule

Read More

Novel assay method detects fungal infections earlier and more accurately

Read More

Carbapenems in development at Korean research institute characterized at ICAAC

Read More

SB initiates phase III trials with fluoroquinolone antibiotic

Read More

Valaciclovir therapy suppresses viral shedding in patients with genital herpes

Read More

Potent, broad-spectrum, orally active 2-pyridone antibacterial enters Abbott pipeline

Read More

Guilford prototype PARP inhibitor proves effective in animal models of stroke, heart attack

Read More

Merck & Co. designs orally active beta3-adrenoceptor partial agonists

Read More

Chirocaine shows increased safety in obstetric population

Read More

IB-367: preclinical results presented at ICAAC support clinical trials in oral mucositis

Read More

AxyS Pharmaceuticals discontinues development of APC-366 for asthma

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 11, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing